ANAPTYSBIO, INC. Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants
ANAPTYSBIO, INC. (ANAB) reported Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants of 0 shares for the 3-month period ending 2017-09-30, per its 10-Q filed 2017-11-07.
Discontinued › Income Statement › Earnings Per Share
us-gaap:IncrementalCommonSharesAttributableToCallOptionsAndWarrants · last filed 2017-11-07
- ANAPTYSBIO, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-09-30 was 0.00 shares.
- ANAPTYSBIO, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2017-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- ANAPTYSBIO, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-09-30 was 0.00 shares.
- ANAPTYSBIO, INC. incremental common shares attributable to dilutive effect of call options and warrants for the quarter ending 2016-06-30 was 28.00K shares.
| Period end | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 3 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 6 month | Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants 9 month |
|---|---|---|---|
| 2017-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 0.00 shares 10-Q · filed 2017-11-07 | |
| 2017-06-30 | 0.00 shares 10-Q · filed 2017-08-10 | 0.00 shares 10-Q · filed 2017-08-10 | |
| 2016-09-30 | 0.00 shares 10-Q · filed 2017-11-07 | 30.00K shares 10-Q · filed 2017-11-07 | |
| 2016-06-30 | 28.00K shares 10-Q · filed 2017-08-10 | 28.00K shares 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |